Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
$36.85M-4.5%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$515K+214%
Arrowhead Research logo
Arrowhead ResearchARWR
$107.88M-5.6%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$12.87M+29.2%
LQD
Liquidia CorporationLQDA
$6.96M+1.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.29M+108%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$686.48M+6.6%
Enterprise value$542.65M-17.8%
P/E11.8×-232×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemJune 30,2026December 31,2025
Operating lease right-of-use assets$1,667$1,212
Current portion of operating lease liabilities$626$419
Operating lease liabilities, less current portion870859
Total operating lease liabilities$1,496$1,278
Weighted average remaining lease term2.23.0
Weighted average discount rate14.3%13.0%

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s operating lease liabilities (total)?
Zevra Therapeutics, Inc. (ZVRA) reported operating lease liabilities (total) of $1.5M in Q2 2026.
How has Zevra Therapeutics, Inc.'s operating lease liabilities (total) changed year-over-year?
Zevra Therapeutics, Inc.'s operating lease liabilities (total) decreased by 5.6% year-over-year, from $1.58M to $1.5M.
What is the long-term trend for Zevra Therapeutics, Inc.'s operating lease liabilities (total)?
Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s operating lease liabilities (total) has grown at a -7.8% compound annual growth rate (CAGR), from $1.91M to $1.28M.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.

Ask your AI about Zevra Therapeutics, Inc.'s operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude